Christina Chambers
Concepts (765)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications | 85 | 2026 | 602 | 15.860 |
Why?
| | Fetal Alcohol Spectrum Disorders | 46 | 2026 | 76 | 11.830 |
Why?
| | Pregnancy Outcome | 57 | 2026 | 503 | 10.150 |
Why?
| | Pregnancy | 248 | 2026 | 7202 | 8.240 |
Why?
| | Prenatal Exposure Delayed Effects | 59 | 2026 | 652 | 8.100 |
Why?
| | Premature Birth | 47 | 2026 | 388 | 7.990 |
Why?
| | Milk, Human | 23 | 2025 | 174 | 7.380 |
Why?
| | Breast Feeding | 27 | 2025 | 446 | 5.100 |
Why?
| | Abnormalities, Drug-Induced | 24 | 2026 | 38 | 5.100 |
Why?
| | Alcohol Drinking | 34 | 2026 | 837 | 4.440 |
Why?
| | California | 50 | 2026 | 471 | 3.900 |
Why?
| | Rheumatic Diseases | 14 | 2025 | 98 | 3.680 |
Why?
| | Infant, Newborn | 104 | 2026 | 6447 | 3.500 |
Why?
| | Antidepressive Agents | 13 | 2025 | 242 | 3.350 |
Why?
| | Autoimmune Diseases | 12 | 2025 | 468 | 3.250 |
Why?
| | Congenital Abnormalities | 17 | 2024 | 109 | 3.210 |
Why?
| | Female | 299 | 2026 | 78844 | 3.170 |
Why?
| | Maternal Exposure | 13 | 2021 | 189 | 3.110 |
Why?
| | Abortion, Spontaneous | 14 | 2022 | 118 | 3.070 |
Why?
| | Lactation | 19 | 2025 | 193 | 2.860 |
Why?
| | Infant, Small for Gestational Age | 17 | 2026 | 118 | 2.770 |
Why?
| | Teratogens | 12 | 2025 | 25 | 2.670 |
Why?
| | Antiphospholipid Syndrome | 3 | 2025 | 37 | 2.480 |
Why?
| | Humans | 315 | 2026 | 145474 | 2.370 |
Why?
| | Arthritis, Rheumatoid | 11 | 2023 | 1180 | 2.220 |
Why?
| | Gestational Age | 34 | 2026 | 987 | 2.130 |
Why?
| | Lupus Erythematosus, Systemic | 7 | 2026 | 238 | 2.110 |
Why?
| | Adult | 135 | 2026 | 40777 | 2.080 |
Why?
| | Mothers | 17 | 2025 | 765 | 2.030 |
Why?
| | Influenza Vaccines | 9 | 2017 | 534 | 2.020 |
Why?
| | Pre-Eclampsia | 11 | 2026 | 206 | 2.000 |
Why?
| | Infant | 73 | 2025 | 10077 | 1.990 |
Why?
| | Cohort Studies | 47 | 2026 | 6013 | 1.990 |
Why?
| | Asthma | 19 | 2024 | 1797 | 1.950 |
Why?
| | Antirheumatic Agents | 10 | 2025 | 307 | 1.940 |
Why?
| | Hypertension, Pregnancy-Induced | 7 | 2023 | 69 | 1.830 |
Why?
| | Prospective Studies | 47 | 2026 | 8057 | 1.810 |
Why?
| | Risk Factors | 67 | 2026 | 10885 | 1.800 |
Why?
| | Child Development | 14 | 2026 | 483 | 1.660 |
Why?
| | Analgesics, Non-Narcotic | 4 | 2026 | 128 | 1.590 |
Why?
| | Drug Hypersensitivity | 2 | 2026 | 90 | 1.590 |
Why?
| | Canada | 13 | 2025 | 431 | 1.530 |
Why?
| | Depression | 12 | 2024 | 1546 | 1.400 |
Why?
| | Glucocorticoids | 5 | 2022 | 531 | 1.360 |
Why?
| | Antiemetics | 2 | 2026 | 51 | 1.350 |
Why?
| | Indians, North American | 4 | 2019 | 597 | 1.330 |
Why?
| | Pregnancy Complications, Cardiovascular | 4 | 2026 | 85 | 1.310 |
Why?
| | Anti-Asthmatic Agents | 11 | 2019 | 260 | 1.300 |
Why?
| | Young Adult | 58 | 2026 | 14218 | 1.290 |
Why?
| | Gastroschisis | 6 | 2018 | 33 | 1.260 |
Why?
| | Influenza, Human | 8 | 2019 | 624 | 1.200 |
Why?
| | Dietary Supplements | 10 | 2021 | 583 | 1.180 |
Why?
| | Hypersensitivity | 4 | 2024 | 254 | 1.160 |
Why?
| | Biological Products | 6 | 2026 | 257 | 1.150 |
Why?
| | Pregnancy Trimester, Second | 7 | 2019 | 83 | 1.140 |
Why?
| | Ethanol | 17 | 2024 | 631 | 1.140 |
Why?
| | Pregnancy Complications, Infectious | 10 | 2026 | 440 | 1.130 |
Why?
| | Arthritis, Juvenile | 2 | 2019 | 60 | 1.130 |
Why?
| | Acetaminophen | 5 | 2024 | 267 | 1.120 |
Why?
| | Cardiovascular Diseases | 5 | 2026 | 2187 | 1.060 |
Why?
| | Colitis, Ulcerative | 3 | 2025 | 148 | 1.060 |
Why?
| | Contraception | 5 | 2020 | 170 | 1.050 |
Why?
| | Lupus Nephritis | 2 | 2025 | 67 | 1.040 |
Why?
| | Research | 3 | 2021 | 430 | 1.040 |
Why?
| | Case-Control Studies | 25 | 2024 | 3623 | 1.040 |
Why?
| | Substance-Related Disorders | 9 | 2026 | 1102 | 1.040 |
Why?
| | Hemangioma | 2 | 2018 | 46 | 1.020 |
Why?
| | Hypoxia-Ischemia, Brain | 2 | 2025 | 49 | 1.020 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2019 | 159 | 1.010 |
Why?
| | Birth Weight | 14 | 2026 | 514 | 0.990 |
Why?
| | Hydroxychloroquine | 3 | 2023 | 65 | 0.990 |
Why?
| | Heart Defects, Congenital | 11 | 2026 | 910 | 0.990 |
Why?
| | Hypothermia, Induced | 2 | 2025 | 95 | 0.980 |
Why?
| | Morning Sickness | 1 | 2026 | 3 | 0.960 |
Why?
| | Child | 50 | 2026 | 22707 | 0.950 |
Why?
| | Product Surveillance, Postmarketing | 5 | 2024 | 74 | 0.940 |
Why?
| | Anti-Inflammatory Agents | 4 | 2025 | 477 | 0.930 |
Why?
| | Crohn Disease | 3 | 2025 | 260 | 0.920 |
Why?
| | Marijuana Abuse | 3 | 2026 | 213 | 0.920 |
Why?
| | Marijuana Use | 5 | 2024 | 222 | 0.920 |
Why?
| | Chorioamnionitis | 2 | 2024 | 50 | 0.920 |
Why?
| | Nausea | 1 | 2026 | 112 | 0.910 |
Why?
| | Hyperemesis Gravidarum | 1 | 2025 | 6 | 0.900 |
Why?
| | Vomiting | 1 | 2026 | 131 | 0.890 |
Why?
| | Infant, Low Birth Weight | 7 | 2026 | 156 | 0.890 |
Why?
| | United States | 33 | 2026 | 16098 | 0.880 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 389 | 0.880 |
Why?
| | Drug Therapy | 2 | 2016 | 84 | 0.880 |
Why?
| | Sudden Infant Death | 2 | 2024 | 39 | 0.880 |
Why?
| | Coronavirus Infections | 2 | 2020 | 383 | 0.870 |
Why?
| | Birth Certificates | 1 | 2024 | 12 | 0.870 |
Why?
| | Psychotherapy, Brief | 2 | 2015 | 40 | 0.860 |
Why?
| | Depressive Disorder | 5 | 2025 | 374 | 0.860 |
Why?
| | Gastrointestinal Agents | 1 | 2025 | 65 | 0.860 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2024 | 409 | 0.820 |
Why?
| | Bulimia Nervosa | 1 | 2024 | 20 | 0.820 |
Why?
| | Nicotine | 4 | 2026 | 331 | 0.810 |
Why?
| | Crotonates | 2 | 2023 | 7 | 0.800 |
Why?
| | Toluidines | 2 | 2023 | 10 | 0.800 |
Why?
| | Hydroxybutyrates | 2 | 2023 | 15 | 0.800 |
Why?
| | Prenatal Care | 11 | 2023 | 309 | 0.790 |
Why?
| | Infant, Newborn, Diseases | 3 | 2021 | 115 | 0.780 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 6 | 2025 | 261 | 0.780 |
Why?
| | Risk | 12 | 2020 | 919 | 0.770 |
Why?
| | Teratology | 3 | 2020 | 3 | 0.770 |
Why?
| | Child, Preschool | 27 | 2026 | 11853 | 0.760 |
Why?
| | Cognition | 5 | 2025 | 1266 | 0.750 |
Why?
| | Retrospective Studies | 32 | 2026 | 17291 | 0.750 |
Why?
| | Plasmalogens | 1 | 2022 | 7 | 0.750 |
Why?
| | Strabismus | 1 | 2023 | 71 | 0.750 |
Why?
| | Anorexia Nervosa | 1 | 2023 | 79 | 0.740 |
Why?
| | Cannabis | 6 | 2025 | 509 | 0.720 |
Why?
| | Anemia | 1 | 2024 | 191 | 0.720 |
Why?
| | Nitriles | 2 | 2023 | 207 | 0.710 |
Why?
| | Prevalence | 13 | 2022 | 2865 | 0.710 |
Why?
| | Male | 76 | 2026 | 72842 | 0.700 |
Why?
| | Metformin | 1 | 2025 | 329 | 0.680 |
Why?
| | Research Design | 4 | 2025 | 1137 | 0.670 |
Why?
| | Inflammatory Bowel Diseases | 4 | 2019 | 364 | 0.670 |
Why?
| | Registries | 9 | 2025 | 2406 | 0.670 |
Why?
| | Hypothermia | 1 | 2021 | 53 | 0.660 |
Why?
| | Isoxazoles | 4 | 2012 | 56 | 0.660 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2016 | 138 | 0.640 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.640 |
Why?
| | Data Collection | 6 | 2023 | 640 | 0.640 |
Why?
| | Interviews as Topic | 6 | 2026 | 910 | 0.640 |
Why?
| | Risk Assessment | 18 | 2025 | 3747 | 0.640 |
Why?
| | Paternity | 2 | 2012 | 5 | 0.630 |
Why?
| | Brain Diseases | 1 | 2021 | 155 | 0.630 |
Why?
| | Prednisone | 2 | 2018 | 224 | 0.620 |
Why?
| | Oseltamivir | 2 | 2019 | 17 | 0.620 |
Why?
| | Dyssomnias | 1 | 2019 | 4 | 0.620 |
Why?
| | Ukraine | 16 | 2022 | 37 | 0.610 |
Why?
| | Medical Records | 2 | 2017 | 192 | 0.610 |
Why?
| | Central Nervous System Depressants | 5 | 2020 | 84 | 0.610 |
Why?
| | Population Surveillance | 5 | 2019 | 484 | 0.610 |
Why?
| | Adalimumab | 1 | 2019 | 55 | 0.600 |
Why?
| | Adolescent | 43 | 2026 | 22529 | 0.600 |
Why?
| | Maternal-Fetal Exchange | 6 | 2022 | 170 | 0.590 |
Why?
| | Live Birth | 6 | 2023 | 81 | 0.590 |
Why?
| | Fever | 4 | 2011 | 319 | 0.580 |
Why?
| | Biological Specimen Banks | 1 | 2020 | 109 | 0.570 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 992 | 0.570 |
Why?
| | Infant, Premature, Diseases | 4 | 2022 | 113 | 0.570 |
Why?
| | Arthritis | 1 | 2019 | 96 | 0.570 |
Why?
| | Migraine Disorders | 1 | 2020 | 114 | 0.560 |
Why?
| | Referral and Consultation | 2 | 2015 | 867 | 0.560 |
Why?
| | Nonprescription Drugs | 2 | 2017 | 69 | 0.560 |
Why?
| | Deprescriptions | 1 | 2019 | 37 | 0.560 |
Why?
| | Telephone | 2 | 2016 | 177 | 0.550 |
Why?
| | Patient Selection | 3 | 2021 | 738 | 0.550 |
Why?
| | Infant Mortality | 5 | 2024 | 128 | 0.550 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 4 | 2026 | 429 | 0.550 |
Why?
| | Postpartum Period | 5 | 2023 | 373 | 0.550 |
Why?
| | Neonatal Screening | 3 | 2024 | 179 | 0.540 |
Why?
| | Socioeconomic Factors | 11 | 2024 | 1323 | 0.540 |
Why?
| | Immunosuppressive Agents | 2 | 2021 | 838 | 0.530 |
Why?
| | Immunologic Factors | 3 | 2016 | 260 | 0.530 |
Why?
| | Mouth Abnormalities | 1 | 2017 | 3 | 0.530 |
Why?
| | Logistic Models | 14 | 2020 | 2134 | 0.530 |
Why?
| | Cross-Sectional Studies | 13 | 2026 | 5904 | 0.530 |
Why?
| | Infant, Premature | 9 | 2026 | 619 | 0.520 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2021 | 2028 | 0.520 |
Why?
| | Substance Abuse Detection | 2 | 2018 | 110 | 0.520 |
Why?
| | RNA, Viral | 2 | 2022 | 692 | 0.520 |
Why?
| | Folic Acid | 2 | 2017 | 198 | 0.520 |
Why?
| | Maternal Age | 7 | 2025 | 128 | 0.510 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 1399 | 0.510 |
Why?
| | Probability | 1 | 2018 | 307 | 0.510 |
Why?
| | Brain | 4 | 2024 | 2947 | 0.510 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 157 | 0.500 |
Why?
| | Aminosalicylic Acids | 1 | 2016 | 10 | 0.500 |
Why?
| | Antidepressive Agents, Second-Generation | 2 | 2012 | 46 | 0.500 |
Why?
| | Physical Examination | 4 | 2023 | 243 | 0.490 |
Why?
| | Odds Ratio | 8 | 2023 | 1082 | 0.490 |
Why?
| | Poverty | 6 | 2020 | 526 | 0.490 |
Why?
| | Models, Statistical | 4 | 2018 | 671 | 0.490 |
Why?
| | Severity of Illness Index | 11 | 2025 | 2930 | 0.480 |
Why?
| | Adrenal Cortex Hormones | 5 | 2026 | 484 | 0.480 |
Why?
| | Alaska Natives | 1 | 2017 | 97 | 0.480 |
Why?
| | Drug Prescriptions | 1 | 2018 | 288 | 0.470 |
Why?
| | Self Report | 3 | 2019 | 870 | 0.470 |
Why?
| | Cannabinoids | 1 | 2018 | 184 | 0.470 |
Why?
| | Hydrocortisone | 1 | 2018 | 298 | 0.470 |
Why?
| | Nasal Decongestants | 1 | 2015 | 9 | 0.470 |
Why?
| | Public Health | 2 | 2019 | 572 | 0.460 |
Why?
| | Multiple Sclerosis | 2 | 2019 | 489 | 0.460 |
Why?
| | Motivational Interviewing | 1 | 2017 | 121 | 0.460 |
Why?
| | Aluminum Hydroxide | 1 | 2015 | 13 | 0.450 |
Why?
| | Contraceptives, Oral | 1 | 2015 | 37 | 0.450 |
Why?
| | Information Services | 4 | 2020 | 43 | 0.450 |
Why?
| | Lipid A | 1 | 2015 | 27 | 0.450 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1061 | 0.440 |
Why?
| | Decision Support Techniques | 3 | 2026 | 477 | 0.440 |
Why?
| | Pain | 2 | 2022 | 789 | 0.440 |
Why?
| | Medical Records Systems, Computerized | 1 | 2015 | 95 | 0.440 |
Why?
| | Fatty Acids | 2 | 2020 | 457 | 0.430 |
Why?
| | Pandemics | 2 | 2020 | 1707 | 0.430 |
Why?
| | Vaccination | 6 | 2025 | 1426 | 0.420 |
Why?
| | Antipsychotic Agents | 1 | 2016 | 211 | 0.420 |
Why?
| | Physician's Role | 2 | 2016 | 223 | 0.420 |
Why?
| | Vitamins | 1 | 2015 | 182 | 0.410 |
Why?
| | Pregnancy Trimester, First | 5 | 2026 | 139 | 0.410 |
Why?
| | Anti-Bacterial Agents | 3 | 2023 | 1923 | 0.410 |
Why?
| | Maternal Behavior | 4 | 2020 | 84 | 0.410 |
Why?
| | Biomarkers | 10 | 2026 | 4295 | 0.410 |
Why?
| | Dyspnea | 1 | 2016 | 250 | 0.400 |
Why?
| | Preconception Care | 6 | 2025 | 50 | 0.400 |
Why?
| | Monte Carlo Method | 1 | 2014 | 147 | 0.400 |
Why?
| | Growth Disorders | 2 | 2012 | 89 | 0.400 |
Why?
| | Adverse Drug Reaction Reporting Systems | 3 | 2025 | 81 | 0.390 |
Why?
| | Fetal Growth Retardation | 7 | 2023 | 593 | 0.390 |
Why?
| | Placenta | 6 | 2023 | 786 | 0.390 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1581 | 0.390 |
Why?
| | Neuropsychological Tests | 7 | 2023 | 1134 | 0.380 |
Why?
| | Environmental Exposure | 6 | 2025 | 578 | 0.370 |
Why?
| | Hospitalization | 9 | 2024 | 2460 | 0.360 |
Why?
| | Neurodevelopmental Disorders | 5 | 2020 | 227 | 0.360 |
Why?
| | Counseling | 1 | 2015 | 400 | 0.350 |
Why?
| | Developmental Disabilities | 4 | 2024 | 281 | 0.350 |
Why?
| | Propensity Score | 1 | 2014 | 377 | 0.350 |
Why?
| | Environmental Pollutants | 2 | 2025 | 139 | 0.340 |
Why?
| | Papillomavirus Vaccines | 1 | 2015 | 296 | 0.340 |
Why?
| | Stroke | 1 | 2020 | 1270 | 0.340 |
Why?
| | Child Behavior | 3 | 2026 | 236 | 0.330 |
Why?
| | Medicaid | 3 | 2022 | 467 | 0.330 |
Why?
| | Anxiety | 4 | 2024 | 1118 | 0.330 |
Why?
| | Critical Pathways | 4 | 2019 | 109 | 0.330 |
Why?
| | Longitudinal Studies | 10 | 2026 | 2953 | 0.320 |
Why?
| | Program Development | 1 | 2013 | 368 | 0.320 |
Why?
| | Electronic Health Records | 2 | 2017 | 1196 | 0.320 |
Why?
| | Etanercept | 2 | 2022 | 60 | 0.320 |
Why?
| | Decision Making | 1 | 2018 | 977 | 0.320 |
Why?
| | Alcoholic Intoxication | 1 | 2011 | 76 | 0.310 |
Why?
| | MicroRNAs | 3 | 2023 | 686 | 0.310 |
Why?
| | United States Food and Drug Administration | 4 | 2020 | 208 | 0.310 |
Why?
| | Perinatal Mortality | 2 | 2024 | 23 | 0.300 |
Why?
| | Lipid Metabolism | 1 | 2013 | 529 | 0.300 |
Why?
| | Fertility Preservation | 2 | 2020 | 55 | 0.300 |
Why?
| | Likelihood Functions | 3 | 2018 | 138 | 0.300 |
Why?
| | Mobile Applications | 2 | 2022 | 199 | 0.290 |
Why?
| | Psoriasis | 1 | 2010 | 115 | 0.290 |
Why?
| | Face | 2 | 2026 | 174 | 0.290 |
Why?
| | Craniofacial Abnormalities | 1 | 2009 | 78 | 0.280 |
Why?
| | Antiviral Agents | 3 | 2024 | 769 | 0.280 |
Why?
| | Prenatal Diagnosis | 4 | 2018 | 196 | 0.280 |
Why?
| | Musculoskeletal Diseases | 2 | 2020 | 90 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 1217 | 0.280 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1547 | 0.280 |
Why?
| | Drug Labeling | 2 | 2020 | 37 | 0.280 |
Why?
| | Problem Behavior | 2 | 2020 | 101 | 0.280 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2025 | 919 | 0.280 |
Why?
| | Gastroenterology | 3 | 2019 | 191 | 0.270 |
Why?
| | Frontal Lobe | 1 | 2009 | 160 | 0.270 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1327 | 0.270 |
Why?
| | Drug Information Services | 1 | 2007 | 11 | 0.270 |
Why?
| | Interpersonal Relations | 1 | 2011 | 397 | 0.270 |
Why?
| | Pharmacokinetics | 1 | 2007 | 33 | 0.270 |
Why?
| | Stress, Psychological | 3 | 2024 | 1146 | 0.270 |
Why?
| | Fetus | 7 | 2018 | 804 | 0.270 |
Why?
| | Patient Care Planning | 2 | 2019 | 170 | 0.260 |
Why?
| | Oligosaccharides | 2 | 2024 | 60 | 0.260 |
Why?
| | Linear Models | 4 | 2023 | 845 | 0.250 |
Why?
| | Alcoholism | 5 | 2021 | 822 | 0.250 |
Why?
| | Lipids | 2 | 2025 | 707 | 0.250 |
Why?
| | Embryo, Mammalian | 1 | 2007 | 234 | 0.250 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2026 | 1419 | 0.250 |
Why?
| | Surveys and Questionnaires | 13 | 2026 | 6066 | 0.250 |
Why?
| | Nails | 1 | 2026 | 14 | 0.240 |
Why?
| | Baths | 1 | 2006 | 14 | 0.240 |
Why?
| | alpha-Fetoproteins | 3 | 2016 | 42 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2378 | 0.240 |
Why?
| | Fetal Development | 3 | 2018 | 298 | 0.240 |
Why?
| | Dicyclomine | 1 | 2026 | 1 | 0.240 |
Why?
| | Doxylamine | 1 | 2026 | 3 | 0.240 |
Why?
| | Infant Death | 2 | 2023 | 9 | 0.240 |
Why?
| | Maternal Health | 4 | 2024 | 50 | 0.240 |
Why?
| | Pregnancy Trimester, Third | 3 | 2020 | 119 | 0.240 |
Why?
| | Pyridoxine | 1 | 2026 | 37 | 0.230 |
Why?
| | Cesarean Section | 3 | 2023 | 230 | 0.230 |
Why?
| | Risk Evaluation and Mitigation | 1 | 2025 | 1 | 0.230 |
Why?
| | Anti-Allergic Agents | 1 | 2006 | 40 | 0.230 |
Why?
| | Cognitive Science | 1 | 2025 | 4 | 0.230 |
Why?
| | C-Peptide | 2 | 2018 | 190 | 0.230 |
Why?
| | Fluoxetine | 2 | 2011 | 56 | 0.230 |
Why?
| | Capillaries | 1 | 2026 | 125 | 0.230 |
Why?
| | Endocrine Disruptors | 1 | 2025 | 41 | 0.230 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2025 | 17 | 0.220 |
Why?
| | Women's Health | 1 | 2007 | 314 | 0.220 |
Why?
| | Reproductive Health | 3 | 2022 | 91 | 0.220 |
Why?
| | Incidence | 5 | 2026 | 2923 | 0.220 |
Why?
| | Reproduction | 2 | 2025 | 208 | 0.220 |
Why?
| | Body Mass Index | 4 | 2023 | 2445 | 0.220 |
Why?
| | Twins | 1 | 2006 | 152 | 0.220 |
Why?
| | Mammary Glands, Human | 1 | 2025 | 68 | 0.220 |
Why?
| | Milk Proteins | 1 | 2025 | 33 | 0.220 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1505 | 0.220 |
Why?
| | Child Behavior Disorders | 1 | 2026 | 118 | 0.220 |
Why?
| | Prescription Drugs | 2 | 2017 | 111 | 0.210 |
Why?
| | Neuropsychology | 1 | 2025 | 44 | 0.210 |
Why?
| | Unemployment | 1 | 2024 | 43 | 0.210 |
Why?
| | Drug Combinations | 1 | 2026 | 396 | 0.210 |
Why?
| | Carbohydrates | 1 | 2025 | 66 | 0.210 |
Why?
| | Pregnancy Trimesters | 5 | 2018 | 20 | 0.210 |
Why?
| | Mammary Glands, Animal | 1 | 2025 | 128 | 0.210 |
Why?
| | Genetic Diseases, Inborn | 1 | 2024 | 45 | 0.210 |
Why?
| | Treatment Outcome | 8 | 2025 | 11772 | 0.210 |
Why?
| | Residence Characteristics | 3 | 2020 | 375 | 0.210 |
Why?
| | Healthcare Disparities | 2 | 2024 | 735 | 0.210 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2018 | 2588 | 0.210 |
Why?
| | Protective Factors | 1 | 2024 | 99 | 0.210 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2024 | 44 | 0.210 |
Why?
| | Checklist | 1 | 2025 | 110 | 0.200 |
Why?
| | Medical Record Linkage | 1 | 2024 | 68 | 0.200 |
Why?
| | Family | 2 | 2023 | 682 | 0.200 |
Why?
| | Apolipoproteins E | 1 | 2024 | 93 | 0.200 |
Why?
| | Oligohydramnios | 1 | 2023 | 16 | 0.200 |
Why?
| | Heart Rate | 4 | 2022 | 855 | 0.200 |
Why?
| | Social Class | 3 | 2020 | 264 | 0.200 |
Why?
| | Eclampsia | 2 | 2021 | 6 | 0.200 |
Why?
| | Fingolimod Hydrochloride | 1 | 2023 | 40 | 0.200 |
Why?
| | Retinopathy of Prematurity | 1 | 2026 | 181 | 0.200 |
Why?
| | Penicillins | 1 | 2023 | 62 | 0.200 |
Why?
| | Follow-Up Studies | 8 | 2021 | 5423 | 0.200 |
Why?
| | Pleurisy | 1 | 2023 | 6 | 0.200 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 85 | 0.190 |
Why?
| | Diet | 3 | 2017 | 1277 | 0.190 |
Why?
| | Thinness | 1 | 2023 | 100 | 0.190 |
Why?
| | Tetralogy of Fallot | 1 | 2024 | 78 | 0.190 |
Why?
| | Educational Status | 3 | 2020 | 466 | 0.190 |
Why?
| | Alanine | 1 | 2024 | 169 | 0.190 |
Why?
| | Databases, Factual | 6 | 2020 | 1490 | 0.190 |
Why?
| | Middle Aged | 11 | 2020 | 36215 | 0.190 |
Why?
| | Wireless Technology | 1 | 2022 | 18 | 0.190 |
Why?
| | Reaction Time | 2 | 2021 | 433 | 0.190 |
Why?
| | Fetal Death | 1 | 2002 | 57 | 0.190 |
Why?
| | Antibodies, Viral | 2 | 2024 | 674 | 0.180 |
Why?
| | Saliva | 1 | 2024 | 246 | 0.180 |
Why?
| | Gaucher Disease | 1 | 2022 | 4 | 0.180 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2022 | 28 | 0.180 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.180 |
Why?
| | Microcephaly | 3 | 2016 | 104 | 0.180 |
Why?
| | Fluorocarbons | 1 | 2023 | 120 | 0.180 |
Why?
| | Administration, Oral | 3 | 2026 | 866 | 0.180 |
Why?
| | Fenfluramine | 1 | 2002 | 17 | 0.180 |
Why?
| | Mastitis | 1 | 2022 | 6 | 0.180 |
Why?
| | Appetite Depressants | 1 | 2002 | 19 | 0.180 |
Why?
| | Phentermine | 1 | 2002 | 14 | 0.180 |
Why?
| | Hypothalamic Diseases | 1 | 2022 | 17 | 0.180 |
Why?
| | Universities | 1 | 2024 | 445 | 0.180 |
Why?
| | Neural Tube Defects | 4 | 2016 | 67 | 0.180 |
Why?
| | Pilot Projects | 4 | 2021 | 1891 | 0.180 |
Why?
| | Disease Management | 3 | 2021 | 653 | 0.180 |
Why?
| | Intestinal Mucosa | 2 | 2025 | 675 | 0.180 |
Why?
| | Epigenesis, Genetic | 2 | 2024 | 679 | 0.180 |
Why?
| | Overweight | 3 | 2022 | 614 | 0.180 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 177 | 0.170 |
Why?
| | Choline | 3 | 2019 | 137 | 0.170 |
Why?
| | Rheumatology | 2 | 2020 | 133 | 0.170 |
Why?
| | Central Nervous System Agents | 1 | 2021 | 7 | 0.170 |
Why?
| | Delphi Technique | 4 | 2025 | 332 | 0.170 |
Why?
| | Fetal Diseases | 2 | 2018 | 194 | 0.170 |
Why?
| | Discrimination Learning | 1 | 2021 | 53 | 0.170 |
Why?
| | Paternal Exposure | 1 | 2021 | 1 | 0.170 |
Why?
| | Stillbirth | 4 | 2026 | 81 | 0.170 |
Why?
| | Diabetes, Gestational | 2 | 2023 | 306 | 0.170 |
Why?
| | Ultrasonography, Prenatal | 2 | 2016 | 295 | 0.170 |
Why?
| | Biological Factors | 1 | 2021 | 39 | 0.170 |
Why?
| | Cannabidiol | 1 | 2023 | 142 | 0.170 |
Why?
| | Pasteurization | 1 | 2020 | 3 | 0.160 |
Why?
| | Infant Behavior | 1 | 2021 | 28 | 0.160 |
Why?
| | Immune System Diseases | 1 | 2021 | 37 | 0.160 |
Why?
| | Psychotropic Drugs | 1 | 2021 | 78 | 0.160 |
Why?
| | Psychomotor Performance | 3 | 2020 | 324 | 0.160 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 31 | 0.160 |
Why?
| | Teratogenesis | 2 | 2018 | 2 | 0.160 |
Why?
| | Heart Block | 2 | 2018 | 41 | 0.160 |
Why?
| | Disruptive, Impulse Control, and Conduct Disorders | 1 | 2020 | 9 | 0.160 |
Why?
| | Alemtuzumab | 1 | 2020 | 15 | 0.160 |
Why?
| | Age Factors | 4 | 2018 | 3342 | 0.160 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2021 | 39 | 0.160 |
Why?
| | Hypertension | 2 | 2019 | 1273 | 0.160 |
Why?
| | Regression Analysis | 2 | 2020 | 1001 | 0.160 |
Why?
| | Term Birth | 2 | 2018 | 25 | 0.160 |
Why?
| | Mental Health | 2 | 2024 | 793 | 0.160 |
Why?
| | Abruptio Placentae | 1 | 2019 | 6 | 0.150 |
Why?
| | Marriage | 1 | 2021 | 121 | 0.150 |
Why?
| | Pediatrics | 2 | 2016 | 1121 | 0.150 |
Why?
| | Circadian Rhythm | 1 | 2024 | 512 | 0.150 |
Why?
| | Placenta Diseases | 2 | 2017 | 20 | 0.150 |
Why?
| | Postpartum Hemorrhage | 1 | 2020 | 28 | 0.150 |
Why?
| | Southwestern United States | 1 | 2019 | 93 | 0.150 |
Why?
| | Pro-Opiomelanocortin | 1 | 2019 | 20 | 0.150 |
Why?
| | Health Personnel | 1 | 2026 | 754 | 0.150 |
Why?
| | Micronutrients | 2 | 2021 | 102 | 0.150 |
Why?
| | Behavioral Symptoms | 1 | 2019 | 41 | 0.150 |
Why?
| | Geographic Mapping | 1 | 2019 | 26 | 0.150 |
Why?
| | Weight Gain | 2 | 2022 | 561 | 0.150 |
Why?
| | Period Circadian Proteins | 1 | 2019 | 33 | 0.150 |
Why?
| | Cities | 1 | 2019 | 138 | 0.150 |
Why?
| | Prognosis | 3 | 2017 | 4316 | 0.150 |
Why?
| | Autism Spectrum Disorder | 1 | 2024 | 422 | 0.150 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2019 | 47 | 0.140 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 83 | 0.140 |
Why?
| | Zika Virus | 1 | 2020 | 136 | 0.140 |
Why?
| | Mood Disorders | 1 | 2020 | 143 | 0.140 |
Why?
| | Health Behavior | 3 | 2017 | 789 | 0.140 |
Why?
| | Placentation | 1 | 2019 | 52 | 0.140 |
Why?
| | Memory Disorders | 1 | 2020 | 197 | 0.140 |
Why?
| | Circulating MicroRNA | 1 | 2019 | 26 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 1140 | 0.140 |
Why?
| | Smoking | 2 | 2020 | 1472 | 0.140 |
Why?
| | Certolizumab Pegol | 1 | 2018 | 5 | 0.140 |
Why?
| | Pain Measurement | 1 | 2021 | 561 | 0.140 |
Why?
| | Executive Function | 2 | 2021 | 470 | 0.140 |
Why?
| | Immune System | 1 | 2020 | 180 | 0.140 |
Why?
| | Algorithms | 4 | 2022 | 1845 | 0.140 |
Why?
| | Vaccines | 1 | 2023 | 388 | 0.140 |
Why?
| | Organic Chemicals | 1 | 2019 | 112 | 0.140 |
Why?
| | Intellectual Disability | 1 | 2020 | 179 | 0.140 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 175 | 0.140 |
Why?
| | Clinical Competence | 1 | 2006 | 1243 | 0.140 |
Why?
| | Depression, Postpartum | 1 | 2020 | 116 | 0.140 |
Why?
| | Fetal Macrosomia | 1 | 2018 | 63 | 0.140 |
Why?
| | Food Supply | 2 | 2017 | 85 | 0.140 |
Why?
| | Zika Virus Infection | 1 | 2020 | 172 | 0.140 |
Why?
| | Precision Medicine | 1 | 2022 | 459 | 0.130 |
Why?
| | Selection Bias | 1 | 2018 | 38 | 0.130 |
Why?
| | Animals | 14 | 2025 | 38030 | 0.130 |
Why?
| | Peptides | 1 | 2024 | 998 | 0.130 |
Why?
| | Electrocardiography | 2 | 2022 | 665 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 303 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 2 | 2019 | 497 | 0.130 |
Why?
| | Vasculitis | 1 | 2018 | 69 | 0.130 |
Why?
| | Benzodiazepines | 1 | 2019 | 168 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 198 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3413 | 0.130 |
Why?
| | Virus Replication | 1 | 2020 | 521 | 0.130 |
Why?
| | Alaska | 1 | 2017 | 77 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 363 | 0.130 |
Why?
| | Vaccines, Inactivated | 1 | 2017 | 70 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1407 | 0.130 |
Why?
| | Albuterol | 1 | 2017 | 76 | 0.130 |
Why?
| | Fertilization in Vitro | 1 | 2018 | 108 | 0.130 |
Why?
| | Hemangioma, Capillary | 1 | 2017 | 14 | 0.130 |
Why?
| | Cocaine-Related Disorders | 1 | 2018 | 133 | 0.130 |
Why?
| | Maternal Health Services | 1 | 2019 | 101 | 0.130 |
Why?
| | Vascular Neoplasms | 1 | 2017 | 18 | 0.130 |
Why?
| | Early Medical Intervention | 1 | 2017 | 62 | 0.130 |
Why?
| | Ibuprofen | 1 | 2017 | 87 | 0.130 |
Why?
| | Suicidal Ideation | 1 | 2023 | 580 | 0.130 |
Why?
| | Pneumonia | 1 | 2023 | 636 | 0.130 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2017 | 85 | 0.120 |
Why?
| | Air Pollution, Radioactive | 1 | 2016 | 2 | 0.120 |
Why?
| | Cesium Radioisotopes | 1 | 2016 | 4 | 0.120 |
Why?
| | Public Health Surveillance | 1 | 2017 | 83 | 0.120 |
Why?
| | Dyslipidemias | 1 | 2018 | 184 | 0.120 |
Why?
| | Chernobyl Nuclear Accident | 1 | 2016 | 5 | 0.120 |
Why?
| | Analgesics, Opioid | 2 | 2026 | 1149 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 2019 | 222 | 0.120 |
Why?
| | Cost of Illness | 1 | 2019 | 324 | 0.120 |
Why?
| | Vascular Diseases | 1 | 2019 | 252 | 0.120 |
Why?
| | Sepsis | 1 | 2023 | 664 | 0.120 |
Why?
| | Epidemiological Monitoring | 2 | 2013 | 69 | 0.120 |
Why?
| | Insurance Coverage | 1 | 2018 | 244 | 0.120 |
Why?
| | Air Pollution | 1 | 2020 | 314 | 0.120 |
Why?
| | Habituation, Psychophysiologic | 1 | 2016 | 57 | 0.120 |
Why?
| | Growth | 1 | 2016 | 49 | 0.120 |
Why?
| | Patient Discharge | 1 | 2022 | 992 | 0.120 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2017 | 118 | 0.120 |
Why?
| | Cytokines | 3 | 2020 | 2067 | 0.120 |
Why?
| | Social Determinants of Health | 1 | 2020 | 308 | 0.120 |
Why?
| | Republic of Korea | 1 | 2015 | 43 | 0.110 |
Why?
| | Immunization | 2 | 2015 | 375 | 0.110 |
Why?
| | Medication Therapy Management | 1 | 2016 | 72 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2016 | 283 | 0.110 |
Why?
| | Mental Processes | 1 | 2015 | 37 | 0.110 |
Why?
| | C-Reactive Protein | 1 | 2018 | 422 | 0.110 |
Why?
| | Indians, South American | 1 | 2015 | 23 | 0.110 |
Why?
| | Geography | 2 | 2019 | 187 | 0.110 |
Why?
| | Food Services | 1 | 2015 | 21 | 0.110 |
Why?
| | Air Pollutants | 1 | 2020 | 405 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2025 | 1161 | 0.110 |
Why?
| | Underage Drinking | 1 | 2015 | 22 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2018 | 321 | 0.110 |
Why?
| | Echocardiography | 1 | 2018 | 647 | 0.110 |
Why?
| | Microbiota | 1 | 2022 | 730 | 0.110 |
Why?
| | Genetic Testing | 3 | 2024 | 480 | 0.110 |
Why?
| | Vitamin D Deficiency | 1 | 2017 | 190 | 0.110 |
Why?
| | Drug Utilization | 1 | 2015 | 168 | 0.110 |
Why?
| | Sex Characteristics | 3 | 2016 | 782 | 0.110 |
Why?
| | Mental Recall | 1 | 2016 | 222 | 0.110 |
Why?
| | Therapy, Computer-Assisted | 1 | 2015 | 63 | 0.100 |
Why?
| | Survival Analysis | 1 | 2017 | 1374 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2017 | 552 | 0.100 |
Why?
| | United Kingdom | 1 | 2015 | 344 | 0.100 |
Why?
| | Comorbidity | 4 | 2020 | 1661 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2017 | 265 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 345 | 0.100 |
Why?
| | Fertility | 1 | 2015 | 173 | 0.100 |
Why?
| | Computer Simulation | 1 | 2018 | 1003 | 0.100 |
Why?
| | Obesity | 4 | 2022 | 3116 | 0.100 |
Why?
| | Disease Progression | 2 | 2019 | 2864 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2021 | 2803 | 0.100 |
Why?
| | Nutritional Status | 1 | 2016 | 353 | 0.100 |
Why?
| | Environment Design | 1 | 2013 | 27 | 0.100 |
Why?
| | Chickenpox | 1 | 1994 | 84 | 0.100 |
Why?
| | Energy Intake | 1 | 2016 | 512 | 0.090 |
Why?
| | Motivation | 1 | 2017 | 600 | 0.090 |
Why?
| | Heart | 1 | 2016 | 626 | 0.090 |
Why?
| | Lung Diseases | 1 | 2019 | 780 | 0.090 |
Why?
| | Internationality | 1 | 2013 | 156 | 0.090 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1329 | 0.090 |
Why?
| | Half-Life | 1 | 2012 | 155 | 0.090 |
Why?
| | Lip | 1 | 2012 | 23 | 0.090 |
Why?
| | Risk-Taking | 1 | 2015 | 323 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 1997 | 0.090 |
Why?
| | Linoleic Acid | 1 | 2012 | 44 | 0.090 |
Why?
| | Hypoglycemia | 1 | 2016 | 479 | 0.080 |
Why?
| | Carbamazepine | 1 | 2011 | 24 | 0.080 |
Why?
| | Interview, Psychological | 1 | 2011 | 95 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 881 | 0.080 |
Why?
| | Sample Size | 1 | 2011 | 121 | 0.080 |
Why?
| | Fathers | 1 | 2011 | 53 | 0.080 |
Why?
| | Sexual Partners | 1 | 2012 | 193 | 0.080 |
Why?
| | Recurrence | 3 | 2020 | 1138 | 0.080 |
Why?
| | Fetal Blood | 2 | 2023 | 327 | 0.080 |
Why?
| | Body Height | 1 | 2012 | 202 | 0.080 |
Why?
| | Head | 1 | 2012 | 121 | 0.080 |
Why?
| | Cholestyramine Resin | 1 | 2010 | 6 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2015 | 777 | 0.080 |
Why?
| | Autoantibodies | 1 | 2018 | 1509 | 0.080 |
Why?
| | Perception | 1 | 2013 | 378 | 0.080 |
Why?
| | Health Surveys | 1 | 2012 | 518 | 0.080 |
Why?
| | Tretinoin | 1 | 2011 | 125 | 0.080 |
Why?
| | Alcohol-Related Disorders | 1 | 2011 | 121 | 0.080 |
Why?
| | Dietary Fats | 1 | 2012 | 308 | 0.080 |
Why?
| | Behavior Therapy | 1 | 2013 | 296 | 0.080 |
Why?
| | Body Size | 1 | 2010 | 88 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 969 | 0.080 |
Why?
| | Cephalometry | 1 | 2009 | 30 | 0.070 |
Why?
| | Time Factors | 3 | 2018 | 7123 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2012 | 558 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1371 | 0.070 |
Why?
| | Adrenergic beta-Agonists | 2 | 2006 | 92 | 0.070 |
Why?
| | Mice | 5 | 2025 | 18329 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2011 | 246 | 0.070 |
Why?
| | Stakeholder Participation | 2 | 2019 | 84 | 0.070 |
Why?
| | Anticholesteremic Agents | 1 | 2010 | 155 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1044 | 0.070 |
Why?
| | Information Dissemination | 2 | 2007 | 224 | 0.070 |
Why?
| | Liver | 1 | 2017 | 1896 | 0.070 |
Why?
| | Embryonic Development | 1 | 2009 | 125 | 0.070 |
Why?
| | Inflammation | 2 | 2021 | 2878 | 0.070 |
Why?
| | Internet | 1 | 2013 | 689 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5983 | 0.070 |
Why?
| | Patient Compliance | 2 | 2016 | 587 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1295 | 0.060 |
Why?
| | Tosyl Compounds | 1 | 2007 | 17 | 0.060 |
Why?
| | Leukotriene Antagonists | 1 | 2007 | 24 | 0.060 |
Why?
| | Phenotype | 1 | 2015 | 3155 | 0.060 |
Why?
| | Mental Disorders | 1 | 2016 | 1163 | 0.060 |
Why?
| | Microscopic Angioscopy | 1 | 2026 | 1 | 0.060 |
Why?
| | Early Diagnosis | 2 | 2019 | 251 | 0.060 |
Why?
| | Moscow | 1 | 2006 | 1 | 0.060 |
Why?
| | Acetates | 1 | 2007 | 78 | 0.060 |
Why?
| | Transcriptome | 2 | 2023 | 1038 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 614 | 0.060 |
Why?
| | Karyotyping | 1 | 2006 | 105 | 0.060 |
Why?
| | Nutrition Surveys | 2 | 2019 | 279 | 0.060 |
Why?
| | Halogenated Diphenyl Ethers | 1 | 2025 | 7 | 0.060 |
Why?
| | Theophylline | 1 | 2006 | 41 | 0.060 |
Why?
| | Parabens | 1 | 2025 | 11 | 0.060 |
Why?
| | Latin America | 1 | 2006 | 96 | 0.060 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2025 | 21 | 0.060 |
Why?
| | Temperance | 1 | 2005 | 20 | 0.060 |
Why?
| | Diet Surveys | 1 | 2006 | 90 | 0.060 |
Why?
| | Isotretinoin | 1 | 2005 | 26 | 0.060 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 1 | 2025 | 27 | 0.060 |
Why?
| | Social Welfare | 1 | 2005 | 27 | 0.060 |
Why?
| | Quinolines | 1 | 2007 | 190 | 0.060 |
Why?
| | Multilingualism | 1 | 2005 | 31 | 0.060 |
Why?
| | Acculturation | 1 | 2005 | 55 | 0.060 |
Why?
| | Alcoholic Beverages | 1 | 2005 | 31 | 0.060 |
Why?
| | Body Temperature | 1 | 2006 | 227 | 0.060 |
Why?
| | Pesticides | 1 | 2025 | 59 | 0.060 |
Why?
| | Perinatal Care | 2 | 2016 | 59 | 0.060 |
Why?
| | Insulin | 1 | 2016 | 2512 | 0.060 |
Why?
| | Dermatologic Agents | 1 | 2005 | 68 | 0.060 |
Why?
| | Phenols | 1 | 2025 | 106 | 0.050 |
Why?
| | Colorado | 1 | 2015 | 4553 | 0.050 |
Why?
| | CLOCK Proteins | 1 | 2024 | 9 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2021 | 2524 | 0.050 |
Why?
| | Transient Tachypnea of the Newborn | 1 | 2024 | 1 | 0.050 |
Why?
| | Carnitine | 1 | 2024 | 91 | 0.050 |
Why?
| | Glucosyltransferases | 1 | 2023 | 4 | 0.050 |
Why?
| | Mutation | 1 | 2015 | 4075 | 0.050 |
Why?
| | Perinatal Death | 1 | 2024 | 26 | 0.050 |
Why?
| | Circadian Clocks | 1 | 2024 | 59 | 0.050 |
Why?
| | Allergy and Immunology | 1 | 2024 | 43 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2025 | 334 | 0.050 |
Why?
| | Urinary Tract Infections | 2 | 2016 | 210 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 2121 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 477 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2025 | 368 | 0.050 |
Why?
| | Haplotypes | 1 | 2024 | 499 | 0.050 |
Why?
| | Safety | 3 | 2014 | 358 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2024 | 2597 | 0.050 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2024 | 107 | 0.050 |
Why?
| | Tooth, Deciduous | 1 | 2022 | 19 | 0.050 |
Why?
| | Infant Health | 1 | 2022 | 24 | 0.050 |
Why?
| | Craniosynostoses | 1 | 2003 | 69 | 0.050 |
Why?
| | Glucosylceramidase | 1 | 2022 | 5 | 0.050 |
Why?
| | Causality | 1 | 2023 | 126 | 0.050 |
Why?
| | Enzyme Replacement Therapy | 1 | 2022 | 15 | 0.050 |
Why?
| | Focus Groups | 1 | 2025 | 569 | 0.050 |
Why?
| | Genome, Human | 1 | 2024 | 420 | 0.050 |
Why?
| | Bias | 1 | 2023 | 197 | 0.050 |
Why?
| | Endocardial Cushions | 1 | 2022 | 7 | 0.040 |
Why?
| | Adenosine | 1 | 2024 | 255 | 0.040 |
Why?
| | Peptide Hydrolases | 1 | 2022 | 105 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2024 | 592 | 0.040 |
Why?
| | Learning | 2 | 2016 | 443 | 0.040 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2025 | 371 | 0.040 |
Why?
| | Rats | 2 | 2021 | 5584 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 214 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 291 | 0.040 |
Why?
| | Mercaptopurine | 1 | 2020 | 15 | 0.040 |
Why?
| | Exercise | 1 | 2013 | 2198 | 0.040 |
Why?
| | Nervous System | 1 | 2021 | 69 | 0.040 |
Why?
| | Cell Movement | 1 | 2025 | 959 | 0.040 |
Why?
| | Organizations | 1 | 2020 | 28 | 0.040 |
Why?
| | Azathioprine | 1 | 2020 | 44 | 0.040 |
Why?
| | Hysterectomy | 1 | 2021 | 138 | 0.040 |
Why?
| | Chromosomes, Human, Y | 1 | 2020 | 37 | 0.040 |
Why?
| | ROC Curve | 1 | 2022 | 617 | 0.040 |
Why?
| | Chromosomes, Human, X | 1 | 2020 | 77 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 450 | 0.040 |
Why?
| | Truncus Arteriosus, Persistent | 1 | 2019 | 7 | 0.040 |
Why?
| | Sex Factors | 1 | 2026 | 2105 | 0.040 |
Why?
| | Lipotropic Agents | 1 | 2019 | 5 | 0.040 |
Why?
| | Halogenation | 1 | 2019 | 22 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2019 | 19 | 0.040 |
Why?
| | Allergens | 1 | 2022 | 386 | 0.040 |
Why?
| | Transposition of Great Vessels | 1 | 2019 | 41 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 124 | 0.040 |
Why?
| | Communication Disorders | 1 | 2019 | 13 | 0.040 |
Why?
| | Norway | 1 | 2019 | 41 | 0.040 |
Why?
| | Motor Disorders | 1 | 2019 | 17 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 64 | 0.040 |
Why?
| | Arrhythmias, Cardiac | 1 | 2021 | 355 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2018 | 24 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2021 | 268 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2021 | 337 | 0.030 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 19 | 0.030 |
Why?
| | Inpatients | 1 | 2023 | 553 | 0.030 |
Why?
| | Postnatal Care | 1 | 2019 | 76 | 0.030 |
Why?
| | Antibodies, Antinuclear | 1 | 2018 | 62 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2019 | 186 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 892 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 2018 | 39 | 0.030 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 23 | 0.030 |
Why?
| | Sampling Studies | 1 | 2018 | 98 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2026 | 1193 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 104 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 200 | 0.030 |
Why?
| | Infant, Postmature | 1 | 2017 | 1 | 0.030 |
Why?
| | Thrombosis | 1 | 2021 | 400 | 0.030 |
Why?
| | Chemokines | 1 | 2018 | 217 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 133 | 0.030 |
Why?
| | Food Assistance | 1 | 2017 | 29 | 0.030 |
Why?
| | Fertilization | 1 | 2017 | 43 | 0.030 |
Why?
| | Disease Outbreaks | 1 | 2020 | 419 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 219 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2018 | 160 | 0.030 |
Why?
| | Microphthalmos | 1 | 2016 | 2 | 0.030 |
Why?
| | Forecasting | 1 | 2019 | 390 | 0.030 |
Why?
| | Sweden | 1 | 2017 | 115 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2017 | 36 | 0.030 |
Why?
| | Obstetrics | 1 | 2019 | 177 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 428 | 0.030 |
Why?
| | Bacteria | 1 | 2022 | 765 | 0.030 |
Why?
| | Parity | 1 | 2017 | 111 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 2020 | 369 | 0.030 |
Why?
| | Metabolomics | 1 | 2022 | 732 | 0.030 |
Why?
| | Fruit | 1 | 2017 | 146 | 0.030 |
Why?
| | Birth Intervals | 1 | 2016 | 23 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2158 | 0.030 |
Why?
| | Trophoblasts | 1 | 2019 | 218 | 0.030 |
Why?
| | Vegetables | 1 | 2017 | 161 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 297 | 0.030 |
Why?
| | Nutrition Assessment | 1 | 2016 | 90 | 0.030 |
Why?
| | Sunlight | 1 | 2017 | 78 | 0.030 |
Why?
| | Sarcosine | 1 | 2015 | 10 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 900 | 0.030 |
Why?
| | Insurance, Health | 1 | 2018 | 310 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 378 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1266 | 0.030 |
Why?
| | Beijing | 1 | 2015 | 2 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2017 | 223 | 0.030 |
Why?
| | Photic Stimulation | 1 | 2016 | 263 | 0.030 |
Why?
| | Personality Disorders | 1 | 2016 | 78 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2017 | 309 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 2016 | 333 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2017 | 369 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 195 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2015 | 330 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2017 | 8333 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 977 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 674 | 0.030 |
Why?
| | Memory | 1 | 2016 | 295 | 0.030 |
Why?
| | Seasons | 1 | 2017 | 538 | 0.030 |
Why?
| | Communication | 1 | 2020 | 975 | 0.030 |
Why?
| | Public Facilities | 1 | 2013 | 3 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1808 | 0.020 |
Why?
| | Biopsy | 1 | 2017 | 1082 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4560 | 0.020 |
Why?
| | Vitamin D | 1 | 2017 | 403 | 0.020 |
Why?
| | Recreation | 1 | 2013 | 29 | 0.020 |
Why?
| | Transportation | 1 | 2013 | 57 | 0.020 |
Why?
| | Patient Care Team | 1 | 2019 | 696 | 0.020 |
Why?
| | Sexually Transmitted Diseases | 1 | 2015 | 168 | 0.020 |
Why?
| | Chondrodysplasia Punctata | 1 | 2012 | 1 | 0.020 |
Why?
| | Virus Diseases | 1 | 2015 | 216 | 0.020 |
Why?
| | Spina Bifida Occulta | 1 | 2012 | 3 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 558 | 0.020 |
Why?
| | Ectodermal Dysplasia | 1 | 2012 | 20 | 0.020 |
Why?
| | Pierre Robin Syndrome | 1 | 2012 | 16 | 0.020 |
Why?
| | Housing | 1 | 2013 | 142 | 0.020 |
Why?
| | Bicycling | 1 | 2013 | 117 | 0.020 |
Why?
| | Schizophrenia | 1 | 2016 | 453 | 0.020 |
Why?
| | Schools | 1 | 2015 | 448 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1508 | 0.020 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2012 | 52 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 2062 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2019 | 2507 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2381 | 0.020 |
Why?
| | Zanamivir | 1 | 2011 | 2 | 0.020 |
Why?
| | Patient Safety | 1 | 2015 | 356 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3542 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1747 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1764 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2009 | 91 | 0.020 |
Why?
| | Self Disclosure | 1 | 2008 | 61 | 0.020 |
Why?
| | Sex Determination Analysis | 1 | 2008 | 10 | 0.020 |
Why?
| | Maternal Welfare | 1 | 2008 | 22 | 0.020 |
Why?
| | Biomedical Research | 1 | 2015 | 717 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 1097 | 0.020 |
Why?
| | Phenylcarbamates | 1 | 2007 | 5 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2007 | 84 | 0.020 |
Why?
| | Aged | 2 | 2017 | 26153 | 0.020 |
Why?
| | Societies, Medical | 1 | 2011 | 899 | 0.020 |
Why?
| | Sulfides | 1 | 2007 | 92 | 0.010 |
Why?
| | Pregnancy Tests | 1 | 2005 | 11 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2008 | 1300 | 0.010 |
Why?
| | Hotlines | 1 | 2004 | 35 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2005 | 571 | 0.010 |
Why?
| | Occipital Bone | 1 | 2003 | 18 | 0.010 |
Why?
| | Supine Position | 1 | 2003 | 37 | 0.010 |
Why?
| | Child Language | 1 | 2003 | 21 | 0.010 |
Why?
| | Indoles | 1 | 2007 | 507 | 0.010 |
Why?
| | Sulfonamides | 1 | 2007 | 583 | 0.010 |
Why?
| | Skull | 1 | 2003 | 162 | 0.010 |
Why?
| | Radiography | 1 | 2003 | 852 | 0.010 |
Why?
| | Sleep | 1 | 2003 | 888 | 0.010 |
Why?
|
|
Chambers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|